Redwood Pharmas IntelliGel drug delivery platform demonstrates positive results in in vitro test
Redwood Pharma’s RP101 ophthalmic drug development therapy uses the IntelliGel drug delivery platform. It has now been tested in an in vitro model to confirm that it is not irritating in the eye. As such, the well-established EpiOcular Eye Irritation Test has been used. Results are good which confirm that IntelliGel works as expected. Further development of the company’s project to treat dry eye disease continues according to plan.
Results from the EpiOcular tests confirm that IntelliGel can become a safe, effective and widely used drug delivery platform for the controlled release of active substances on the eye’s surface. Redwood Pharma’s RP101 development project can become the first ophthalmic pharmaceutical therapy to take advantage of the IntelliGel drug delivery platform.
“Pharmaceutical drug development has many phases that build a compelling body of research and clinical evidence which ultimately demonstrates the medical, as well as commercial, advances over conventional therapies. Redwood Pharma has access to data that demonstrate safety and efficacy of the active substance in RP101 in two phase II clinical trials and is generating convincing data around the new formulation with IntelliGel. The EIT results are a positive step to realizing the commercial value of both IntelliGel and RP101,” says CEO Martin Vidaeus.
For more information:
Martin Vidaeus, CEO, Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.se
About Redwood Pharma AB (publ)
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company's first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma's strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information see www.redwoodpharma.com.